

Table 2.4
Counts (Annualized Percentages) of Participants with Self-Reported Outcomes by Age at Enrollment and Race/Ethnicity for HT Participants Who Did Not Report a Prevalent Condition at Baseline

Data as of: September 30, 2015; Events through September 30, 2015

Outcome	Total	Age at Enrollment			
		50-54	55-59	60-69	70-79
Number randomized	27347	3420	5413	12360	6154
Mean follow-up (months)	171.4	184.5	182.3	172.9	151.3
Hospitalizations					
Ever	19542 (5.00%)	1909 (3.63%)	3394 (4.13%)	9175 (5.15%)	5064 (6.53%)
Two or more	14089 (3.61%)	1197 (2.28%)	2222 (2.70%)	6743 (3.79%)	3927 (5.06%)
Conditions/Procedures					
Diabetes (treated)	4214 (1.13%)	612 (1.21%)	868 (1.11%)	1987 (1.17%)	747 (1.01%)
Gallbladder disease ^{1,2}	2117 (1.18%)	282 (1.14%)	443 (1.18%)	988 (1.24%)	404 (1.07%)
Hysterectomy	1194 (0.49%)	151 (0.48%)	282 (0.52%)	562 (0.51%)	199 (0.43%)
Glaucoma ²	3201 (1.55%)	286 (1.02%)	548 (1.28%)	1519 (1.64%)	848 (1.97%)
Osteoporosis ²	6111 (2.99%)	475 (1.69%)	962 (2.25%)	2954 (3.22%)	1720 (4.09%)
Osteoarthritis ³	7965 (3.17%)	1125 (2.71%)	1730 (2.91%)	3637 (3.31%)	1473 (3.67%)
Rheumatoid arthritis ²	1696 (0.82%)	211 (0.76%)	341 (0.81%)	763 (0.83%)	381 (0.87%)
Intestinal polyps	6478 (1.78%)	829 (1.63%)	1394 (1.78%)	3143 (1.90%)	1112 (1.62%)
Lupus	438 (0.11%)	52 (0.10%)	93 (0.11%)	203 (0.11%)	90 (0.12%)
Kidney stones ^{2,3}	769 (0.37%)	94 (0.34%)	143 (0.34%)	346 (0.37%)	186 (0.41%)
Cataracts ^{2,3}	8648 (4.69%)	505 (1.80%)	1344 (3.19%)	4577 (5.50%)	2222 (7.20%)
Hypertension treated w/pills	10691 (3.79%)	1351 (3.16%)	2194 (3.42%)	4911 (3.93%)	2235 (4.49%)
COPD ⁴	1081 (0.99%)	102 (0.71%)	250 (1.10%)	554 (1.12%)	175 (0.80%)
Macular degeneration ⁵	2738 (1.21%)	147 (0.49%)	359 (0.75%)	1359 (1.32%)	873 (1.97%)
Alzheimer's disease ⁵	2226 (0.99%)	75 (0.25%)	208 (0.44%)	1070 (1.04%)	873 (1.97%)
Parkinson's disease ⁵	323 (0.14%)	24 (0.08%)	55 (0.12%)	175 (0.17%)	69 (0.16%)

Outcomes	Race/Ethnicity					
	Am Indian/ Alaskan Native	Asian/Pacific Islander	Black/African American	Hispanic/ Latino	White	Unknown
Number randomized	130	527	2738	1537	22030	385
Mean follow-up (months)	154.7	156.2	161.0	148.6	174.9	161.5
Hospitalizations						
Ever	90 (5.37%)	283 (4.13%)	1854 (5.05%)	817 (4.29%)	16239 (5.06%)	259 (5.00%)
Two or more	72 (4.30%)	167 (2.43%)	1308 (3.56%)	473 (2.49%)	11894 (3.70%)	175 (3.38%)
Conditions/Procedures						
Diabetes (treated)	24 (1.61%)	83 (1.29%)	575 (1.77%)	314 (1.78%)	3155 (1.02%)	63 (1.31%)
Gallbladder disease ^{1,2}	13 (1.72%)	32 (0.89%)	187 (0.97%)	129 (1.46%)	1730 (1.19%)	26 (1.08%)
Hysterectomy	4 (0.59%)	11 (0.23%)	78 (0.51%)	60 (0.54%)	1026 (0.50%)	15 (0.47%)
Glaucoma ²	16 (1.72%)	60 (1.57%)	408 (2.06%)	190 (1.67%)	2480 (1.48%)	47 (1.73%)
Osteoporosis ²	32 (3.40%)	141 (3.70%)	348 (1.68%)	338 (3.08%)	5159 (3.12%)	93 (3.36%)
Osteoarthritis ³	46 (3.96%)	161 (3.26%)	755 (3.27%)	527 (3.88%)	6361 (3.10%)	115 (3.35%)
Rheumatoid arthritis ²	15 (1.70%)	30 (0.79%)	272 (1.39%)	219 (1.96%)	1125 (0.67%)	35 (1.27%)
Intestinal polyps	32 (2.06%)	102 (1.65%)	688 (2.01%)	298 (1.64%)	5278 (1.77%)	80 (1.69%)
Lupus	3 (0.18%)	5 (0.07%)	48 (0.13%)	32 (0.17%)	346 (0.11%)	4 (0.08%)
Kidney stones ^{2,3}	9 (1.00%)	25 (0.65%)	82 (0.39%)	62 (0.56%)	583 (0.35%)	8 (0.28%)
Cataracts ^{2,3}	44 (5.02%)	143 (4.26%)	790 (4.23%)	450 (4.15%)	7108 (4.80%)	113 (4.61%)
Hypertension treated w/pills	57 (4.74%)	184 (3.80%)	867 (4.65%)	610 (4.23%)	8842 (3.70%)	131 (3.71%)
COPD ⁴	8 (1.71%)	8 (0.37%)	82 (0.77%)	31 (0.50%)	939 (1.06%)	13 (0.85%)
Macular degeneration ⁵	10 (0.92%)	23 (0.57%)	129 (0.60%)	77 (0.66%)	2474 (1.34%)	25 (0.78%)
Alzheimer's disease ⁵	9 (0.83%)	24 (0.59%)	203 (0.95%)	94 (0.81%)	1875 (1.02%)	21 (0.66%)
Parkinson's disease ⁵	2 (0.19%)	6 (0.15%)	21 (0.10%)	14 (0.12%)	277 (0.15%)	3 (0.09%)

¹ "Gallbladder disease" includes self-reports of both hospitalized and non-hospitalized events.

² Data not collected for WHI Extension Studies 2005-2015.

³ These outcomes have not been self-reported on all versions of Form 33 during WHI follow-up. The annualized percentages are corrected for the different amounts of follow-up.

⁴ Data only collected during the WHI Extension Study 2010-2015.

⁵ Data only collected during the WHI Extension Studies 2005-2015.

